Previous Close | 50.22 |
1-Year Change | 58.52% |
6-Months Change | -15.64% |
3-Months Change | -11.05% |
Moving Avg (50d) | 54.08 |
Moving Avg (200d) | 60.126 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.82M |
Beta (3-Years) | 1.12 |
Revenue Growth (ttm) | -94.73% |
Net Profit Margin (ttm) | -6739.96% |
Return On Assets (ttm) | -71.12% |
EPS (ttm) | -5599.57 |
PE Ratio (ttm) | -0.01 |
Dividend Yield | % |
Asset Description: | Cytokinetics, Incorporated |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
50.082 | 51.555 | 52.537 | 54.01 | 56.465 | 58.92 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia